Insider filing · BGNE
John Oyler
Chief Executive Officer
profile →
John Oyler sold $14.6M of BeiGene (BGNE)
Executed Mar 7 2025, disclosed Mar 7 2025, the same day.
Value, as filed
$14.6M
58,590 sh across 13 lots
Executed
Mar 7 2025
the trade date, as filed
Disclosed
Mar 7 2025
0 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
JOJohn Oyler (Chief Executive Officer) filed 11 Form 4 reports in the trailing twelve months (0 purchases, 11 sales), most often in BeOne Medicines AG (ONC). The largest single filing was $89.3M of ONC (282,921 sh across 16 lots, as filed), executed Jul 15.
The name
BGNE
BGNE
BGNE · 23 filings in 24 months
ticker →
Insider filings, newest first→
View the original filing at www.sec.gov→
Other filings by John Oyler in BGNE
BGNESALE
BeiGene, Ltd.
$10.0M41,210 sh across 9 lots
Exec Mar 10 2025
Filed Mar 12 2025 · 5:30 PM ET BGNESALE BeiGene, Ltd. $10.4M
40,009 sh across 7 lots
Exec Mar 6 2025
Filed Mar 7 2025 · 5:30 PM ET BGNESALE BeiGene, Ltd. $24.7M
101,000 sh across 12 lots
Exec Mar 3 2025
Filed Mar 5 2025 · 5:30 PM ET BGNESALE BeiGene, Ltd. $3.6M
15,475 sh across 10 lots
Exec Oct 8 2024
Filed Oct 10 2024 · 5:30 PM ET